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Next Generation Sequencing Technology has revolutionized our ability to study the contribution of rare genetic variation to heritable
traits. However, existing single-marker association tests are underpowered for detecting rare risk variants. A more powerful approach
involves pooling methods that combine multiple rare variants from the same gene into a single test statistic. Proposed pooling methods
can be limited because they generally assume high-quality genotypes derived from deep-coverage sequencing, which may not be avail-
able. In this paper, we consider an intuitive and computationally efficient pooling statistic, the cumulative minor-allele test (CMAT).
We assess the performance of the CMAT and other pooling methods on datasets simulated with population genetic models to contain
realistic levels of neutral variation. We consider study designs ranging from exon-only to whole-gene analyses that contain noncoding
variants. For all study designs, the CMATachieves power comparable to that of previously proposedmethods.We then extend the CMAT
to probabilistic genotypes and describe application to low-coverage sequencing and imputation data. We show that augmenting
sequence data with imputed samples is a practical method for increasing the power of rare-variant studies. We also provide a method
of controlling for confounding variables such as population stratification. Finally, we demonstrate that our method makes it possible
to use external imputation templates to analyze rare variants imputed into existing GWAS datasets. As proof of principle, we performed
a CMAT analysis of more than 8 million SNPs that we imputed into the GAIN psoriasis dataset by using haplotypes from the 1000
Genomes Project.Introduction
The Genome-Wide Association Study (GWAS) is a powerful
tool for analyzing common variation across the human
genome.1 In recent years, GWASs have identified risk
alleles for a wide range of complex human diseases.2
However, most of these alleles provide only small to
moderate increases in risk and contribute little to the over-
all heritability of the disease.3 Because it is unlikely that the
remaining heritability can be completely explained by
undetected common variants with even lower effects,4
heritable factors besides common variation must con-
tribute to complex diseases. The Common Disease-Rare
Variant Hypothesis proposes that some of themissing heri-
tability can be explained by low frequency variants with
larger effect sizes.5,6 Under this model, the contribution of
individual variants to population prevalence is small, but
the combined effect of numerous rare variants can account
for an appreciable fraction of the prevalence. This model is
feasible if risk variants are subject to weak purifying selec-
tion and is supported by the fact that allele frequencies
for protein-altering mutations are more heavily skewed
toward rare variants than those for neutral variants.7
Previously, technological limitations hampered the
ability to affordably assay and test rare variants in large
population-based samples. However, recent advances in
next-generation sequencing technology now provide
the potential to detect all polymorphisms in a genomic1Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, U
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rather than rely on indirect linkage disequilibrium (LD)-
based methods. Already, candidate-region resequencing
has led to the discovery of numerous rare variants contrib-
uting to phenotypic variation and complex disease in
humans. Resequencing of coding regions and consensus
splice sites in NPC1L1 and PCSK9 has led to the identifica-
tion of multiple rare nonsynonymous mutations collec-
tively associated with variation in sterol absorption and
plasma levels of LDL-C.9,10
Individually testing each variant identified by rese-
quencing is not a powerful strategy because it requires
stringent multiple testing correction and power dimin-
ishes with decreasing allele frequencies.11 To avoid these
issues, several groups have proposed various statistical
methods that instead pool together multiple rare variants
from the same gene and jointly test them for associa-
tion.9,12–14 The recent literature has addressed two related
questions in rare-variant testing: first, the question of
how to effectively combine multiple rare variants in a
gene into a single test and, second, how to weight variants
on the basis of some prior assumption about the likelihood
of functionality. Cohen et al. performed a pooled analysis
of rare variants in NPC1L1 and identified nonsynonymous
variants observed only in cases or only in controls and
used Fisher’s exact test to compare the distributions of
cases and controls carrying these variants.9 Li and Leal pro-
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that pools variants below a specified minor-allele fre-
quency (maf) and then dichotomizes individuals on the
basis of whether they carry a variant allele at one of the
pooled sites.12 A multivariate statistic is used for jointly
analyzing the set of pooled variants together with more
common variants in the region.
Madsen and Browning introduced two features in the
weighted sum statistic (WSS).13 First, the WSS accumulates
rare-variant counts within the same gene for each indi-
vidual rather than collapsing on them. Second, it intro-
duces a weighting term to emphasize alleles with a low
maf in controls. The result is that each individual receives
a quantitative genetic score that is more informative than
a qualitative score, especially for individuals harboring
more than one rare allele in the region. The scores for all
samples are ordered, and the WSS is computed as the
sum of ranks for cases. One determines significance by
permuting affection status and re-ranking. The ranking
protects against outliers but becomes computationally
expensive for large sample sizes.
Price et al.14 showed that the power gain of weights
based on minor allele frequency is dependent on the rela-
tionship between risk-allele frequency and likely effect
size; this relationship is in turn is dependent on selection
strength. The weights used by Madsen and Browning, for
example, correspond to strong purifying selection. If this
model is correct, the WSS provides a significant power
gain over the previous methods. To generate a test that is
powerful under multiple evolutionary models, Price et al.
proposed a variable maf-threshold approach. For a given
frequency threshold, one computes a likelihood ratio
statistic to compare summed minor-allele counts for vari-
ants below the maf threshold for cases and controls. The
likelihood ratio statistic is maximized across a range of
frequency thresholds so that the statistic is adapted to
the underlying model of selection.
All pooling statistics are subject to variant misspecifica-
tion—that is, potential inclusion of neutral variants or
exclusion of risk variants. Study designs to date have opted
to minimize inclusion of neutral variants by limiting anal-
ysis to nonsynonymous coding variants of candidate
genes.11 The power of this strategy depends on the cumu-
lative effect of rare risk variants that are exonic. Although
coding variants are most likely to be functional, they
account for only a tiny fraction of variation in the genome.
Numerous pieces of evidence indicate that noncoding vari-
ants play an extensive role in disease etiology. Eighty-eight
percent of trait-associated variants identified by GWAS
have occurred outside of known coding regions.2 Large
portions of noncoding regions in the human genome
are subject to negative selection, indicating a functional
purpose to the sequence.15 In addition, noncoding risk
variants have already been verified for numerous dis-
eases.16–18 Resequencing noncoding intronic and regula-
tory regions could enable detection of these more elusive
risk variants but also presents new technical and analytical
challenges to rare-variant analysis. In particular, noncod-The Americaning sequence contains substantially more neutral variation
than coding regions.
Existing pooling methods have not been carefully as-
sessed under a paradigm where many risk variants reside
outside exons. Instead, these methods have only been
considered for fairly optimal testing conditions in which
each gene is assumed to have few variants, most of which
are causative.12,13 Moreover, previously published pooling
methods assume high-quality rare-variant genotypes that
are only available through deep-coverage sequencing.
Exon-only studies can attain high-quality genotype calls
because sequencing is limited to relatively small regions.
Generating high-quality sequence data of larger genomic
regions (including whole-genome sequencing) is still
expensive, which limits the number of samples that can
be sequenced at deep coverage for a given study. Instead,
cost-effective strategies such as low-coverage sequenc-
ing19 and genotype imputation20 will be used to produce
sample sizes large enough to powerfully analyze rare vari-
ants. Genotype calls from these methods are less precise
than deep sequencing, generating probabilistic rather
than exact genotypes. Thus, tests applied to whole-gene
sequence data containing both coding and noncoding
regions must accept probabilistic genotypes and be robust
to potentially high inclusion rates for neutral variants.
In this article, we consider a simple pooling statistic, the
cumulative minor-allele test (CMAT) and show that it is
easily extended to accommodate practical analysis consid-
erations such as qualitative covariates and probabilistic
genotypes. The CMAT is closely related to the tests
described in Madsen and Browning13 and in Price et al.14
in that it aggregates allele counts rather than collapsing
on them. Like these methods, the CMAT jointly analyzes
sets of variants that occur in the same gene and that would
otherwise be missed by a standard single-marker analysis.
Because the power of single-marker tests is dependent on
study sample size and risk-allele frequency, the CMAT is
computed on variants with a maf below a preset threshold.
In this paper we especially focus on markers with
a maf <5% and hereafter refer to these as rare variants.
One computes the CMAT statistic by summing rare-
allele counts for sites predicted to be functionally relevant
separately for cases and controls. Our test statistic is analo-
gous to the single marker allelic c2 statistic typically used
to test for allele frequency difference between cases and
controls. Significance is determined by permutation to
account for correlation between pooled variants.
We compare the power of several pooling methods on
case-control sequencing datasets simulated with popula-
tion genetic models designed to mimic the overall level
of diversity seen in European HapMap samples. We create
a disease model of allelic heterogeneity by placingmultiple
rare risk variants in the population. The effect size for each
risk variant is determined by allele frequency to ensure low
power for a single marker test. Because our datasets contain
realistic levels of neutral variation, we can consider the
effect of variant misspecification, both inclusion of neutralJournal of Human Genetics 87, 604–617, November 12, 2010 605
variants and exclusion of causal variants, in study designs
ranging from exon-only to whole-gene analysis. We show
that, depending on the proportion of noncoding risk vari-
ants, whole-gene designs can be more powerful than exon-
only designs even if they include a large number of neutral
variants.
The form of the CMAT statistic conveniently allows for
categorical covariates and probabilistic genotypes. These
extensions allow rare-variant analysis for datasets contain-
ing imputed genotypes or low-coverage sequence data as
well as common confounding variables such as population
stratification. We demonstrate the importance of these
extensions by analyzing two previously unconsidered
rare-variant study designs. First, we simulate rare-variant
datasets containing spurious associations created by popu-
lation stratification. Ignoring the stratification leads to an
elevated Type I Error rate, and controlling for it with the
covariate form of the CMAT maintains the desired a-level.
Second, we present a study design consisting of both
sequenced and imputed samples. We assume that the
sequenced samples are used for identification of novel
rare variants in a region of interest and that they serve
as templates for imputation of genotypes for these variants
into the remaining (non-sequenced) samples. While care-
fully accounting for the uncertainty involved in imputing
rare variants, we simulate datasets for this study design and
analyze them with the CMAT.We show that using imputa-
tion to increase the sample size of a sequencing dataset can
substantially improve power. Hence we predict that impu-
tation will provide a powerful cost-saving strategy for
future resequencing studies. Moreover, our results suggest
that one could use existing resources such as the 1000
Genomes Project to reanalyze existing GWAS datasets by
imputing rare variants and performing tests such as the
CMAT.
Finally, we illustrate the possibility of reanalyzing GWAS
datasets without resequencing samples. As a proof of prin-
ciple, we imputed more than 8million SNPs into the GAIN
psoriasis GWAS dataset by using CEU haplotypes from the
1000 Genomes Project. This dataset had previously been
augmented with genotypes imputed from HapMap haplo-
types and analyzed with a single-marker association test.21
That analysis identified numerous common risk loci that
were subsequently replicated; these included several vari-
ants in the HLA region on chromosome 6. We reanalyzed
3000 genes with at least two rare variants (maf % 5%) by
using the CMAT. One gene, SKIV2L, located on chromo-
some 6 near the HLA region, maintained a significant
test statistic after we corrected for multiple testing.Methods
Below, we develop notation for exact and probabilistic
genotype calls, then introduce the CMAT along with three
alternative rare-variant tests. Subsequently, we describe our
algorithm for simulating case-control sequencing data on606 The American Journal of Human Genetics 87, 604–617, Novembthe basis of population genetic models. Finally, we provide
details for our application of the CMAT to the GAIN Psori-
asis dataset.
Data Structure
We assume a dataset of NA cases and NU controls. Let
xij˛ 0;1;2gf be the true number of minor alleles at the jth
variant site in the ith case. Let yij be the same value for
the ith control. We consider two possible types of genotype
calls in the data: exact calls, discrete values from 0; 1;2gf
giving the observed minor-allele count, and probabilistic
calls, consisting of a posterior probability mass function
Pð,Þ giving the likelihood for each possible minor-allele
count. Exact genotypes reflect the high-confidence calls
possible in deep-coverage sequencing data, whereas the
probabilistic calls represent the uncertainty in low-cover-
age sequencing and imputation. In the dataset, we define
the observed value for the jth variant site in the ith case to be
Xij ¼
8<
:
xij; for exact genotype callsP2
n¼0
nP

xij ¼ n

; for probabilistic genotype calls:
That is, we assume the true minor-allele count is
observed if an exact call is made; otherwise, we observe
the minor-allele count that is expected on the basis of
the posterior probability distribution. Similarly, we define
Yij for the j
th variant site in the ith control and replace xij
with yij.
Cumulative Minor-Allele Test
Weassume the genetic data are partitioned into a collection
of discrete testing units, genomic regions to be individually
tested for association with disease susceptibility. The most
natural choice for a testing unit is a single gene, but highly
conserved nongenic regions or pathways containing mul-
tiple genes are also suitable. Assume F > 1 variants in
the testing unit, each with a weighting factor wjR0,
ðj ¼ 1;.FÞ. It is possible to filter a variant out of the anal-
ysis by setting the respective weight to zero or emphasize
its presence by assigning a large weight. For this paper, wj
is a simple indicator function that identifies variants
included in the analysis (it is described in more detail
later). Note that a testing unit containing only a single
variant with positive weight is equivalent to a single-
marker test on that variant.
We first describe application of the CMAT to a dataset
containing exact genotype calls for all NA cases and all
NU controls. Let mA ¼
PNA
i¼1
PF
j¼1
wjXij and mU ¼
PNU
i¼1
PF
j¼1
wjYij be
the weighted minor-allele counts across all sites in the
testing unit for cases and controls, respectively. Then
MA ¼
PNA
i¼1
PF
j¼1
wjð2 XijÞ and MU ¼
PNU
i¼1
PF
j¼1
wjð2 YijÞ are
therefore the weighted major-allele counts across all sites
for cases and controls, respectively. We define the CMAT
statistic SCMAT to beer 12, 2010
SCMAT ¼ NA þNU
2NANU
P
j wj
3
ðmAMU mUMAÞ2
ðmA þmUÞðMA þMUÞ (1)
The statistic SCMAT is derived from the standard Pearson
c2 statistic for testing independence between allele
frequency and disease status in a single-marker association
test. However, SCMAT does not have an asymptotic c
2 distri-
bution because independent counts are required for the
asymptotic properties to be valid. Because we sum over
multiple sites in a testing unit, and because some of these
sites might be in LD with each other, the counts are not
independent. Instead, we determine the statistical sig-
nificance of SCMAT by permuting affection status while
holding the genetic data fixed. For each permuted realiza-
tion, SCMAT is recomputed, and the p value is defined as
the proportion of permutations with a test statistic greater
than or equal to the observed statistic.
In the presence of qualitative covariate data on potential
confounders, the weighted allele counts are computed
separately within each covariate level, and the form of
SCMAT is changed to a Cochran-Mantel-Haenszel-like
statistic. Assume a qualitative covariate c ¼ 1;.;C. Using
similar notation, we define the observed value for the jth
variant site in the ith case of the cth covariate class to be
Xijc ¼
8<
:
xijc; for exact genotype callsP2
n¼0
nP

xijc ¼ n

; for probabilistic genotype calls:
Similarly, we define Yijc for the j
th variant site in the ith
control of the cth covariate class and replace xijc with yijc.
Assume NA;c cases and NU;c controls within the c
th covari-
ate class and Nc ¼ NA;c þNU;c. Weighted allele counts are
then computed within each covariate class separately.
Let mA;c ¼
PNA ;c
i¼1
PF
j¼1
wjXijc and mU;c ¼
PNU ;c
i¼1
PF
j¼1
wjYijc be the
weighted minor-allele counts across all sites in the testing
unit for cases and controls, respectively, in the cth covariate
class. Then MA;c ¼
PNA;c
i¼1
PF
j¼1
wjð2 XijcÞ and MU;c¼
PNU ;c
i¼1
PF
j¼1
wj
ð2 YijcÞ are the weighted major-allele counts across sites
for cases and controls, respectively, of the cth covariate
class. We define the covCMAT statistic ScovCMAT to be
ScovCMAT ¼
P
c mA;c 
NA;cðmA;c þmU;cÞ
Nc
2
P
c
NA;cNU;cðmA;c þmU;cÞðMA;c þMU;cÞ
2N3c
P
j wj
: (2)
Statistical significance is determined by permuting case-
control status while keeping the genetic and covariate data
fixed. Equation (2) resembles the Cochran-Mantel-Haens-
zel c2 statistic and simplifies to Equation (1) when C ¼ 1.
We now consider a dataset containing NAseq cases and N
U
seq
controls with exact genotype calls and NA NAseq cases and
NU NUseq controls with probabilistic calls. Computation of
SCMAT (Equation 1) remains the same except expectedThe Americanminor allele counts replace exact counts for imputed
samples. One again determines significance by permuting
affection status. However, to account for the difference in
quality between the two data types, one must shuffle affec-
tion status separately for exact and probabilistic calls. That
is, for all permutations, the number of cases and controls
with exact genotype counts must remain constant. Failure
to modify the permutation method in this manner can
affect type I error, especially for unbalanced designs
(NAseqsN
U
seq).
Alternative Rare-Variant Methods
We compared the performance of the CMAT to three alter-
native rare-variant methods. First, we implemented Li and
Leal’s collapsing method,12 which compares number of
rare-variant carriers in cases to the number in controls. Let
the indicator variable Xi denote whether the i
th case carries
at least one rare variant at a site of interest, as follows
Xi ¼

1; wjXij > 0 for any 1%j%F
0 otherwise:
Yi is analogously defined to indicate controls carrying at
least one rare variant. Then X ¼ PNA
i¼1
Xi and Y ¼
PNU
i¼1
Yi are,
respectively, the number of cases and controls carrying at
least one rare variant. The Pearson c2 statistic,
c2COLL ¼
ðNA þNUÞ3 ðXNU  YNAÞ2
NANUðXþ YÞðNA þNU  X YÞ
tests the null hypothesis that cases and controls are equally
likely to be carriers of a rare variant. c2COLL has an asymp-
totic c2 distribution with one degree of freedom.
Next, we considered a private-allele test similar to the
method used by Cohen et al,9 to compare the number of
rare variants unique to either cases or controls. For this
test we required an equal number of cases and controls
(NA ¼ NU ). A site is defined to be private if it is polymor-
phic in either cases or controls but monomorphic in the
other group. The minor allele at a private site is called
a private allele. For example, the minor allele at the jth
site is private to cases if
PNA
i¼1
Xij > 0 but
PNU
i¼1
Yij ¼ 0. Under
the null hypothesis, rare variants are not associated with
disease risk, and private alleles are therefore equally likely
to occur in cases and controls. This is tested formally
with a c2 test in the following manner: Let npriv be the total
number of private alleles in the dataset and nA and nU the
number of private alleles unique to cases and controls,
respectively (npriv ¼ nA þ nU ). Define
c2PRIV ¼

nA  npriv
2
2
þ

nU  npriv
2
2
npriv
2
Under the null distribution of no association, c2PRIV is
asymptotically c2 distributed with one degree of freedom.Journal of Human Genetics 87, 604–617, November 12, 2010 607
Figure 1. Relationship between Minor-Allele Frequency and
Relative Risk in Our Disease Model
The relative risk is chosen such that a single marker test of 1000
cases and 1000 controls performed at a ¼ 105 on a risk variant
with the specified maf has a maximum power of 10%. Relative
risks for variants with a maf < 103 were truncated to 6.As with the CMAT and collapsing test, the private-allele
test considers only variants with positive weighting
terms.
Finally, we implemented the WSS as described by Mad-
sen and Browning.13 For the ith individual in the dataset,
one computes a genetic score defined as gi ¼ PF
j¼1
wjXij.
The genetic scores for all samples in the dataset (cases
and controls combined) are sorted, and the sum of ranks
of genetic scores for cases, x ¼ P
i˛cases
rankðgiÞ, is computed.
Statistical significance of x is determined by permutation.
Madsen and Browning recommend increasing the weight
of rare variants by defining weighting terms according to
maf in controls. We do not directly consider the question
of how to weight rare variants in this paper. Therefore,
we applied a simple uniform weighting scheme to all tests.
However, for comparative purposes, we include applica-
tion of the WSS and CMAT in which the weights defined
in Madsen and Browning are used (Figure S2). The three
alternative methods have been formally defined only for
exact genotypes; thus, we limit power comparisons to data-
sets containing only exact genotype calls.
Simulations
Deep-Sequence Datasets
We simulated deep-sequence datasets containing exact
genotype calls for an equal number N of cases and con-
trols. We first created a population of ten thousand
100 kb haplotypes by using the coalescent simulator cosi
with parameters chosen to reflect characteristics seen in
the European HapMap samples.22 Let ntot be the total
number of polymorphic sites among the ten thousand
population haplotypes. Denote the allele at the jth site on
the ith haplotype as Aij, where Aij ¼ 0 if the major allele
is present and Aij ¼ 1 if the minor allele is present
ði ¼ 1;.;10;000 and j ¼ 1;.;ntotÞ. We fixed a maximum
allele frequency pmax for risk alleles and randomly chose
k sites with maf < pmax to be causative. Let cj ¼ 1 if the jth
variant site is selected to be causative and cj ¼ 0 if it is
neutral.
For each risk variant, we assigned an effect size that
ensured that a single-marker association test would have
a low probability of being statistically significant. Specifi-
cally, we computed the relative risk gp necessary for a risk
variant with maf ¼ p to have 10% power in a 1 degree of
freedom c2 test of 1000 cases and 1000 controls performed
at a ¼ 105 (Figure 1). As a result, rarer variants are as-
signed larger relative risks, although we capped relative
risks for variants with maf < 103 at six. Assuming the
maf for the jth variant is p, we set the relative risk at that
site to be RRj ¼ gcjp .
Assuming a multiplicative effect between causative vari-
ants, the penetrance fi for haplotype i is
fi ¼
ﬃﬃﬃ
b
p
3
Y
j jAij¼1
RRj;608 The American Journal of Human Genetics 87, 604–617, Novembwhere b is the risk for an individual with wild-type
(non-risk) alleles at all causative sites and is set to ensure
that the population prevalence remains fixed at a desired
level.
We then sampled diploid cases and controls by using
Bayes’ Theorem to randomly drawing two haplotypes
conditional on disease status. For example, if we assume
unconditionally that each of the ten thousand popula-
tion haplotypes is equally likely to be selected, the proba-
bility that the ith and jth haplotypes will be chosen for a
case is
Pr

hi;hj j case
 ¼ Prcase j hi;hj3PrðhiÞ3Prhj
PrðcaseÞ
¼ fi3fj
10;00023PrðcaseÞ:
We treat the unconditional probability of being a case
(population prevalence) as a fixed parameter in our simula-
tions.
After the construction of a dataset, we mimicked a bioin-
formatic annotation process to determine the set of vari-
ants predicted to be functional and therefore included in
the analysis. Each observed variant was randomly labeled
as either ‘‘included’’ or ‘‘excluded’’ from the analysis condi-
tional on whether it was causative or neutral. Define pc to
be the probability that a causative variant is predicted to
be functional and therefore included in the analysis. Like-
wise, pn is the same probability for neutral variants. Then,
if we let Ij be an indicator for inclusion in the analysis, the
jth variant is included with probability
Pr

Ij ¼ 1
 ¼  pc; cj ¼ 1
pn; cj ¼ 0:
We treated the values pc and pn as parameters to simulate
study designs with alternative inclusion thresholds. Usinger 12, 2010
the functional annotations, we defined the weighting
terms used in our simulations
wj ¼

Ij; mafj%b
0 mafj > b:
(3)
This weighting scheme therefore acted as a filter to retain
variants that had a maf%b and were predicted to be func-
tional in the annotation step.
Imputation Datasets
Next, we created datasets containing exact genotypes for
Nseq cases and controls that were assumed to have been
sequenced at deep coverage. We also created datasets con-
taining probabilistic genotypes for an additional N Nseq
imputed cases and controls. Thus, in contrast to our
deep-sequence simulations, where we assumed deep-
sequence data for all samples, here we assumed deep-
sequence data for only a fraction of the total sample size.
It was computationally infeasible to phase and impute
genotypes for each simulated dataset; therefore, we drew
haplotypes forN cases and controls by using the previously
described method and replaced the true minor-allele
counts with expected minor-allele counts for the imputed
portion of the sample. Expected minor-allele counts were
drawn from empirical sampling distributions created via
independent imputation runs (see Appendix A). Individual
draws were made conditional on the true minor-allele
count at the locus to be imputed and the number of times
the minor allele at that site was observed in the sequenced
samples. We created separate empirical distributions for
Nseq ¼ 100, 200, and 400. Only sites polymorphic among
the sequenced samples were eligible for inclusion in the
analysis. Singletons in the sequenced samples cannot be
accurately phased and were therefore not imputed. Hence,
the minor allele must be observed at least twice in the
sequenced samples to be imputed.
Stratified Datasets
To demonstrate the covariate form of the CMAT statistic,
we simulated datasets containing population stratification.
To do so, we used cosi to simulate sets of haplotypes that
reflect variation observed in European and African popula-
tions.22 We drew datasets containing N cases and N
controls under the null hypothesis of no risk variants
(k ¼ 0); however, we preferentially chose haplotypes
from the African population to be cases. For each sample
in a dataset, we first chose a population of origin for the
sample. We let p be the probability that a control is derived
from the African population and pþ d, ðd > 0Þ, to be the
probability that a case is derived from the African pop-
ulation. Controls and cases are therefore drawn from
the European population with probability 1 p and
1 p d, respectively. Once population of origin was
determined, we randomly selected two haplotypes from
the appropriate population to create a diploid sample.
We analyzed each simulated dataset with both the CMAT
and the covCMAT and controlled for population of origin
in the latter. When applying the covCMAT, we assumedThe Americanthat the true population of origin was known for each
sample.
Simulation Settings
We fixed the population disease prevalence at 1%
throughout the simulations. Under our disease model,
increasing the number of causative sites k while holding
prevalence constant increases the proportion of disease
prevalence explained by variation at the locus. We focused
our analysis on risk alleles with a maf %5% by setting
parameters pmax and b to 0.05. However we repeated our
analysis while restricting risk variants to a maf %1% and
report those results as well. Because causative sites were
chosen at random and the allele frequency spectrum was
heavily shifted toward extremely low frequencies, approx-
imately 95% of risk alleles in our simulations have
frequency < 1% even for simulations with pmax ¼ 0:05.
We estimated power for each test at different parameter
settings as the proportion of simulated datasets with statis-
tically significant p values (based on a minimum of at least
1000 simulated datasets). We report power at a critical level
of a ¼ 0:01, for which we assume that the sequenced
region contains several genes to be tested.
GWAS Application
We imputed 8.2 million autosomal SNPs into the GAIN
Psoriasis dataset by using 112 CEU haplotypes from the
August 2009 release of the 1000 Genomes Project as a refer-
ence. We filtered the imputed SNPs by removing all vari-
ants with very low estimated imputation accuracy (bR2 <
0.3). We annotated SNPs discovered in the 1000 Genomes
Project Pilot by using a custom Perl script. The tool reports
for each SNP the gene locus (if available) and the predicted
protein effect, based on a set of curated transcripts from
Refseq and GenBank. We included in our analysis SNPs
annotated as missense, nonsense, or splice-site mutation
or an untranslated region (UTR). We filtered out variants
with a maf > 5% and pooled the remaining variants
together by genes. That is, we used the following weighting
strategy:
wj ¼
8<
:
1; mafj%0:05 and UTR; missense;
nonsense; or splice-site
0; otherwise:
Results
Deep-Coverage Sequencing Datasets
To evaluate the performance of the CMAT, we used coa-
lescent simulations to generate realistic case-control
sequence data for a 100 kb region of interest, representing
the exons, introns, and surrounding regulatory regions for
a large gene. A dataset of N ¼ 1000 cases and controls
drawn from a populationwith k ¼ 15 rare (maf%5%) caus-
ative sites contained, on average, S ¼ 1565 segregating
variable sites with a mean pairwise sequence differenceJournal of Human Genetics 87, 604–617, November 12, 2010 609
Figure 2. Power to Analyze Deep-
Sequencing Datasets for a Range of Inclu-
sion Probabilities
Each dataset contains exact genotypes for
N ¼ 1000 cases and controls based on
k ¼ 15 causative variants in the popula-
tion. Along the vertical axis, we vary the
probability of (incorrectly) including a
neutral variant (pn) in the analysis, and
along the horizontal axis we vary the prob-
ability of (correctly) including a causative
variant (pc). The height of the bars in
each cell indicates the power for the four
tests at a ¼ 0:01.p ¼ 0:00114. Of the observed sites, 1272 had a maf%5%,
and we observed 12:4 of the 15 risk alleles. A larger dataset
with N ¼ 2000 cases and controls contained an average of
1556 polymorphic sites with frequency < 5% and 14:1 of
the 15 risk alleles. Larger sample sizes therefore increase
both the number of risk alleles observed in the sample
and the number of neutral variants.
We mimicked functional filtering by analyzing only
a subset of the variants observed in a dataset. If they
were observed, causative variants were ‘‘predicted’’ to be
functional and therefore were included in the analysis
with probability pc ; neutral variants were included with
probability pn. Because few of the observed variants are
actually causative, pn is approximately the overall propor-
tion of rare variants included in the analysis, and pc can
be thought of as the success rate for including causal
variants.
We determined practical values for pc and pn by investi-
gating the distribution of functional annotations for genic
SNPs in the dbSNP database.23 Of genic SNPs with at least
one annotation, approximately 1.6% were denoted as
nonsynonymous coding or splicing variants (nonsense,
missense, frameshift, or altered splice-site mutations), 1%
were synonymous coding variants, 2.7% occurred in the
UTR, and 5.3% occurred outside the transcribed region
of the gene. Intronic SNPs accounted for the remaining
class of variants. Thus, an overall inclusion rate ðpnÞ of610 The American Journal of Human Genetics 87, 604–617, November 12, 20101%–2% roughly corresponds to ana-
lyzing only nonsynonymous vari-
ants, whereas extending the analysis
to include variants in the UTR and
outside the transcribed region has an
inclusion rate of approximately 10%.
We computed power for the rare-
variantmethods on amisspecification
grid with values of pn between 0 and
0.1 and pc between 0.2 and 1.0. First
we computed the type I error for
each test by setting k ¼ 0. The CMAT,
collapsing method, and WSS each
maintained the desired false-positive
rate for all values of pn. Type I error
for the private allele test was initiallyconservative for smaller values of pn, and then increased
with the number of variants included until it became
anti-conservative for larger values of pn (Figure S1).
Increased false positives for the private-allele test were
probably due to the inclusion of variants in high pairwise
LD in the calculation, in violation of the independence
assumption required for the asymptotic distribution.
In the presence of causative variants (k > 0), the power
to identify a gene depended on the inclusion parameters
pc and pn (Figure 2). We discuss results generated with
a sample size of N ¼ 1000 and k ¼ 15 causative variants;
results for k ¼ 7 and k ¼ 30 were similar (not shown).
When all variants were correctly specified (pc ¼ 1; pn ¼ 0),
the CMAT, WSS, and collapsing test attained power near
100%, and the private test attained a power of 72%,
indicating that each test is quite powerful under perfect
filtering. However, power for each test dropped when we
allowed for misspecification. Increasing the probability of
including neutral variants (pn[) reduced power. Decreasing
the probability of including causative variants (pcY) also
lowered power.
A comparison of power between tests illustrates that the
CMATandWSS had nearly identical performance andwere
the most powerful tests at all levels of misspecification
considered. The private-allele test had power <20% for
most parameter settings. Power for the CMAT, WSS, and
collapsing test was nearly identical when only a small
Figure 3. Application of the covCMAT to Control for Population
Stratification
Cases were preferentially sampled from a population containing
a larger number of rare variants. Failure to account for population
stratification leads to inflated false-positive rates for the CMAT.
When applied with the covariate correction, the covCMAT main-
tained the appropriate type I error.number of neutral variants were included in the test
statistic (pn%0:02). Here, the absolute power for the three
tests was heavily dependent on the inclusion rate for
causal variants; it increased from 30% up to 95% as the
number of included causal variants increased.
The CMAT and WSS showed a clear power gain over the
collapsing method for larger neutral variant-inclusion
probabilities. In fact, the power gain was greatest when
filtering accuracy was poorest. The CMAT had a power
of 24%, as opposed to 11% for the collapsing test when
pn ¼ 0.1 and pc ¼ 0.2. This trend continued for values of
pn > 0:1 (data not shown). This difference is caused by
the way the different tests account for individuals with
more than one rare variant of interest. For larger values
of pn, individual samples are increasingly likely to contain
multiple rare variants. By directly testing the number of
rare variants rather than the number of rare-variant
carriers, the CMAT and WSS have additional power over
the collapsing test.
Appropriately weighting variants in the test statistic
might further improve power. However, it is presently
unclear which weighting strategy is the most powerful,
and it is likely that it will differ from case to case. Although
we do not directly address the issue of most powerful
weighting scheme in this paper, we computed power for
both the CMAT and WSS by using the weighting scheme
described by Madsen and Browning.13 Under this scheme,
allele counts for the jth variant are weighted by the inverse
of the standard deviation of allele count in controls.
To facilitate comparison, we included only variants with
a maf below our predetermined threshold (b ¼ 0:05) in
the analysis. The maf-based weights correspond more
closely to our disease model (Figure 1) than do the simple
uniform weights and therefore provided a more powerful
analysis for both methods except when misspecification
rates were highest (Figure S2). Conditional on weighting
scheme, the CMAT and WSS had similar power across the
grid.
To assess the influence of variants with a maf of 1%–5%
on the presented results, we repeated all simulations while
restricting attention to variants with a maf %1% (ie
b ¼ 1%; pmax ¼ 1%). The misspecification grid for these
settings (Figure S3) showed that overall power for each
test was slightly lower than in the presented results. The
noticeable change was that for the largest values of pn
and pc, the WSS showed a power advantage, whereas the
CMAT and the collapsing test had similar power.
For the remainder, simulation results are based on inclu-
sion parameters of pn ¼ 0.1 and pc ¼ 0.8 so that they reflect
a whole-gene analysis strategy that includes nonsynony-
mous coding and splice-site mutations plus variants in the
UTR and potential regulatory regions flanking the gene.
Covariate Correction
Next, we created datasets in which samples were drawn
from two distinct populations meant to resemble Euro-
pean and African haplotypes. We simulated the datasetsThe Americanunder the null hypothesis of no association (k ¼ 0) but
preferentially drew cases from the African population.
Because the African haplotypes contain more rare varia-
tion than do the European haplotypes, the datasets con-
tain a spurious association between disease status and an
excess of rare variants. Datasets contained N ¼ 1000 cases
and controls drawn from the African population with
probability pþ d; d > 0 and p, respectively. We analyzed
each dataset at a ¼ 0:01 with the CMAT and the covCMAT
and controlled for population of origin in the latter.
We present results for p ¼ 0:5 and 0%d%0:25 (Figure 3).
Ignoring the population stratification resulted in an
elevated CMAT type I error, which increased sharply for
d > 0:025. The magnitude of this increase is affected by
the inclusion probability for the summary statistics. For
strategies that attempt to capture all variants near a gene
(shown here), the false-positive rate is substantially larger
than for strategies focusing on exonic variation. Control-
ling for ancestry by including it as a covariate into the
covCMAT maintained the desired type I error across all
values of d we considered.
Imputation Datasets
The CMAT is easily applied to imputation datasets contain-
ing probabilistic genotype calls. To consider the potential
of a study design combining sequenced and imputed sam-
ples, we simulated exact genotype calls for the sequenced
samples and probabilistic genotypes for the remaining
samples. We considered a design with an equal number
of cases and controls sequenced in a 100 kb region of
interest and genotyped for tagSNPs in a 1Mb encompass-
ing region. Imputed samples were assumed to be geno-
typed for the same set of tagSNPs. In this design, variants
observed at least twice in the sequenced samples were
imputed in the nonsequenced samples.Journal of Human Genetics 87, 604–617, November 12, 2010 611
Figure 4. Comparison of CMAT Power for Deep Sequencing and
Imputation Study Designs
From left to right, the bars show power at a ¼ 0:01 for a deep-
sequencing dataset with N ¼ 200, an imputation dataset with
Nseq ¼ 200 and N ¼ 2000, and a deep-sequencing dataset with
N ¼ 2000. For each, we used the whole-gene inclusion threshold
(pn ¼ 0:1; pc ¼ :8).
Figure 5. CMAT Power for Imputation Datasets
Datasets contain exact genotypes for Nseq sequenced cases and
controls and probabilistic genotypes based on imputation for
the remaining samples. The top line shows CMAT power when
all samples are sequenced ðNseq ¼ NÞ and serves as an upper bound
for power at a fixed total sample size N. We report power
at a ¼ 0:01 by using the whole-gene inclusion threshold
(pn ¼ 0:1; pc ¼ 0:8).We found that the addition of imputed samples to a fixed
number of sequenced samples can provide a considerable
power gain over analyzing only the sequenced samples
(Figure 4). A whole-gene CMAT analysis of datasets drawn
from a population containing k ¼ 15 causative variants
and constrained to N ¼ Nseq ¼ 200 sequenced cases and
controls has a power of 14%. Augmenting these sequenced
samples with an additional 1800 imputed cases and con-
trols (total sample size N ¼ 2000) increases power to 48%.
This compares favorably with the optimalN ¼ 2000 design
that sequences all samples and has a power of 66%. Thus,
the additional information from imputed samples recov-
ered much but not all of the power of a fully sequenced
dataset.
We extended our analysis to a wide range of sample sizes
with N from 200 to 5000 and considered the effect of
sequencing Nseq ¼ 100, 200, or 400 samples for each N.
The CMAT had a well controlled type I error when it was
applied to datasets simulated with k ¼ 0 causative variants
(data not shown). We present results for an analysis
involving whole-genome inclusion parameters and k ¼ 15
causative variants in the population (Figure 5). Power
curves for inclusion thresholds that reflect an exon-only
analysis (pn ¼ 0:02; pc ¼ 0:4) were slightly lower across all
considered values of N (data not shown). For comparison,
we also computed CMAT power for a dataset containing
exact genotypes for all samples (i.e., Nseq ¼ N). We found
that for a given total sample size N, CMAT power increased
with the number of sequenced samples. AtN ¼ 3000, data-
sets containing 100, 200, and 400 sequenced samples had
powers of 48%, 56%, and 65%, respectively. Attaining
similar power in a set of fully sequenced samples requires
N ¼ Nseq ¼ 1000, 1500, and 2000 samples, respectively.
The dependence of power on the number of sequenced
individuals is driven by three factors. First, replacing an
exact genotype with a probabilistic genotype results in
a loss of information. Thus, for a fixed sample size, datasets612 The American Journal of Human Genetics 87, 604–617, Novembcontaining fewer sequenced samples suffer a larger infor-
mation loss. Second, increasing the number of sequenced
samples increases the chance that a risk allele is observed
at least twice and can therefore be imputed. Of k ¼ 15
risk alleles in the simulations with maf <5%, an average
of 3.2 were observed at least twice among 100 sequenced
cases and controls. This number increased to 5.0 and 7.5
for datasets with 200 and 400 sequenced cases and
controls, respectively. Third, imputation accuracy for an
individual allele improves as that allele is observed more
often in the sequenced samples. Sequencing a larger
number of samples increases the number of times a risk
allele is observed, and thus improves imputation accuracy
for that allele.
We repeated the imputation simulations by using 1%
maf parameter settings (Figure S4). We observed only a
small reduction in power compared to the analysis with
maf %5%. Only datasets with 100 sequenced cases and
100 sequenced controls showed a notable reduction in
power. For Nseq ¼ 100, 200, and 400 sequenced cases and
controls, a study with total sample size of N ¼ 3000 had
powers of 38%;52%, and 63%, respectively. Hence, pro-
vided there is a sufficiently large set of sequenced
templates, imputation of rare variants is a useful strategy,
even if variants with a maf < 1% are of particular interest.Application to GAIN Psoriasis Data
Our simulation study assumed that imputation templates
were sequenced individuals from the study sample. It is
feasible to instead use haplotypes from a public dataset
as the imputation templates. This has the advantage
that it allows rare-variant analysis in any existing GWAS
dataset without requiring additional sequencing by the
investigator.er 12, 2010
Table 1. Summary of the Top Result from CMAT Analysis of the GAIN Psoriasis Dataset, into which 8.2 Million SNPs were imputed on the
basis of 112 CEU Haplotypes from the 1000 Genomes Project as a Reference
SKIV2L Variant maf Function Imputation bR2 Single-Markerp Value Correlation between Imputed Genotypes
rs17201466 0.0496 UTR 0.98 0.0018 1.000
rs36038685 0.0109 R324W 0.99 0.1210 0.016 1.000
rs3911893 0.0427 D887N 0.94 0.0029 0.055 0.006 1.000
rs106287 0.0359 V917M 0.91 0.0888 0.059 0.027 0.034 1.000
SKIV2L was statistically significant after Bonferroni correction (CMAT p < 106). SKIV2L is located on 6p21.33, 700 kb away from HLA-C, a known psoriasis suscep-
tibility locus. The table lists the maf, functional annotation, imputation accuracy bR2, and single-marker p value of individual variants included in the pooled
statistic. The last columns contain the pairwise correlations between imputed minor-allele counts.As proof of principle for this approach, we applied the
CMAT to the GAIN Psoriasis (MIM 177900) dataset consist-
ing of 1,359 psoriasis cases and 1,400 unaffected controls
of white European ancestry. We imputed 8.2 million auto-
somal SNPs into the dataset by using 112 CEU haplotypes
from the August 2009 release of the 1000 Genomes Project
as our reference panel. Previously, others had imputed this
dataset for 2.5 million SNPs by using the CEU HapMap
samples and analyzed it with a standard single-marker
test for association.21 The strongest signal for association
(rs12191877, single marker p ¼ 4 3 1053) was located
13 kb upstream of the HLA-C (MIM 142840) gene, a previ-
ously known psoriasis locus on chromosome 6. Ten of the
top 18 loci identified in the initial analysis were subse-
quently replicated in a larger, independent sample.
To apply the CMAT, we assigned the imputed SNPs to
genes and retrieved functional annotations for genic
variants (see Methods). We retained only SNPs with
maf < 0:05 and annotated these as nonsynonymous,
splice-site, or UTR. In total, 2889 genes containing two
or more SNPs after filtering were analyzed with the
CMAT. Of the genes tested, 55% contained two SNPs,
23% contained three SNPs, 11% contained four SNPs, and
the remaining 11% contained five or more SNPs. None of
the ten replicated SNPs from the original analysis remained
after filtering, and only three genes (IL12B [MIM 161561],
TSC1 [MIM 605284] and TNFAIP3 [MIM 191163]) near
a replicated signal were included in the CMAT analysis.
After Bonferroni correction for the number of genes
tested, one gene, SKIV2L, achieved statistical significance
ðp< 106; p< 33103 after Bonferroni correction) (MIM
600478). SKIV2L is located on 6p21.33, 700 kb away
from HLA-C, the previously implicated psoriasis-suscepti-
bility locus. The SKIV2L testing unit contained four
imputed variants with a maf < 0.05 (Table 1). Although
each variant trended toward significance in the single-
marker test, no individual p value is sufficient to explain
the level of significance observed in the CMAT. Genotypes
for these variants were uncorrelated, indicating they are
probably on different haplotype backgrounds and there-
fore independently contribute to the CMAT statistic. Thus,
the significance of the SKIV2L CMAT statistic is driven by
the cumulative effect of the four variants. Because imputa-The Americantion accuracy, indicated by bR2, is high for each variant, it is
unlikely that the observed signal is the result of low impu-
tation quality.
Analysis of common variation in the HLA region
indicated the potential for additional functional variants
in the same or different genes after conditioning on
rs12191877. Our result for SKIV2L might indicate such
an additional psoriasis locus in this region and makes
SKIV2L an interesting candidate for further investigation.Discussion
We described the CMAT, a simple method for jointly
testing multiple rare variants in case-control sequence
data; the CMAT can be easily extended to deal with typi-
cal challenges of modern genomic studies. Notably, our
statistic accepts expected minor-allele counts from pro-
babilistic genotypes, making it applicable to both low-
coverage sequencing and imputed data. The statistic can
incorporate qualitative covariates and thus allow correc-
tion for confounders such as population stratification.
Moreover, the CMAT is both computationally fast and
straightforward to implement.
We assessed the CMAT by applying it to simulated case-
control sequencing datasets specifically designed to con-
tain realistic levels of neutral variation. We also considered
three alternative testing strategies, a private-allele test
similar to the one used by Cohen et al.,9 the collapsing
test described by Li and Leal,12 and the weighted sum
statistic (WSS) of Madsen and Browning.13 We considered
levels of variant misspecification that are representative of
exon-only sequencing to entire genic regions. Our results
indicated that the strategy of focusing on exonic variants
is appropriate if most rare risk variants are located in exons.
However, if the majority of rare risk variants are located
in regulatory regions, then analyzing all rare variants
together, both exonic and nonexonic, can be more power-
ful than analyzing only the exonic variants. That is, the
increase in signal from including noncoding risk variants
can outweigh the additional noise of noncoding neutral
variants. Comparing the different tests, we noticed that
the CMAT, WSS, and collapsing test were equally powerfulJournal of Human Genetics 87, 604–617, November 12, 2010 613
for the exon-only model. However, the CMATand theWSS
were more robust to variant misspecification and were
therefore significantly more powerful when we analyzed
data representative of whole-gene analysis. The CMAT
provides similar power to that of the WSS and is computa-
tionally more efficient. Because the WSS is based on
ranking individuals, its computation time is bounded by
the theoretical maximum of O(nlog(n)); the computation
time of the CMAT is linear with sample size. This difference
can be substantial for analysis of large sample sizes in
genome-wide studies.
A pooling statistic that accepts probabilistic genotypes
dramatically increases the range of possible rare-variant
study designs. Our simulations demonstrated the potential
of including genotypes from both direct sequencing and
imputation in the test statistic. Because genotypes for
rare variants are generally imputed with higher error rates
than common variants, it is important to propagate this
uncertainty into the analysis by using expected minor-
allele counts, as opposed to most likely genotype, in the
CMAT. Our simulation results show that one can gain
substantial power by augmenting sequencing datasets
with imputed samples. In particular, sequencing only
a fraction of available individuals and imputing the
remainder can recoup much of the power of a study that
sequences all samples and provide a major cost reduction.
Other methods for testing rare variants can most likely be
adapted so that there is a comparable gain of efficiency
from imputed data. Note that we modeled the sequencing
of an equal number of cases and controls, but more power-
ful sequencing strategies for observing risk alleles might
exist, for example, one such strategy might involve
sequencing mainly cases.24
We also provided an example of a rare-variant analysis
that does not require sequencing. Instead, rare variants
can be imputed into existing GWAS datasets from publicly
available reference panels. Single-marker tests have limited
power to detect an association at these imputed variants
because of both lowmaf and high uncertainty in imputing
rare variants.25 Pooling these variants and testing their
cumulative effect is more powerful and could uncover
additional signals in the data. We used the haplotypes
from the CEU samples in the 1000 Genomes Project to
impute rare variants into the existing GAIN Psoriasis
GWAS dataset. Our analysis shows that the CMAT can
identify interesting genes that cannot be found by single-
marker tests. The identified gene (SKIV2L) contains mul-
tiple rare variants, none of which achieved genome-wide
significance in a single-marker test. SKIV2L resides in the
HLA region of chromosome 6, which is thought to harbor
multiple psoriasis susceptibility genes. However, the bio-
logical interpretation is not clear. SKIV2L is not an obvious
candidate for psoriasis. Although SKIV2Lmight be a psori-
asis locus, it is also conceivable that multiple rare variants
in SKIV2L tag the same functional common variant in
another gene, and the observed signal might be the result
of reverse synthetic association.26 Further analysis is neces-614 The American Journal of Human Genetics 87, 604–617, Novembsary to validate this finding. The analysis was limited by
the size of our reference panel, which contained only
112 haplotypes. Only 2889 genes contained two or more
coding variants with a maf <0.05 in this panel and were
thus eligible for the pooled analysis. Future releases from
the 1000 Genomes Project should provide low-coverage
sequencing of 2500 individuals and deep-exome rese-
quencing of the same 2500 individuals.19 This will increase
the number of imputable rare variants and make this anal-
ysis method more powerful.
Accurate prediction of functionally relevant sites and
appropriate weighting will reduce variant misspecification
and could further improve the power of pooling methods.
The weighting scheme proposed by Madsen and Brown-
ing13 is based on allele frequency and is most powerful
for risk variants under relatively high purifying selection.14
Alternatively, variants can be weighted according to
predictions of molecular function. In practice, bioinfor-
matic tools such as PolyPhen27 and SIFT28 are useful in pre-
dicting deleterious potential but are typically limited to
coding variants. Determining functionality of noncoding
variants is more difficult, and although databases con-
taining known phenotype-altering noncoding variants
exist (PupaSuite,29 for example), these are not applicable
to novel variants. Instead, identifying conserved regula-
tory regions within noncoding portions of a gene will be
crucial in determining which noncoding variants have
phenotype-altering potential and should be included in
an analysis.30 For this paper, rather than attempting to
optimize weights for our specific disease model, we
assumed very simple uniform weights and focused on the
overall performance of our test with respect to variant mis-
specification and imputation. However, we have included
a general weighing term into the statistic to allow any
desired scheme to be incorporated.
Our simulation results are based on several underlying
assumptions. Like other methods, our method assumes
that all rare variants pooled together have the same type
of effect. That is, either all are causative, the likely model
if risk variants are under purifying selection,5 or they are
all protective. If this assumption is violated and causal
and protective alleles are combined into a single statistic,
pooling methods will lose power. Our results also depend
on our disease model, specifically the range of allele fre-
quencies and effect sizes for risk variants. The true fre-
quency spectrum for risk alleles will depend on the
strength of purifying selection at the locus and can range
from extremely rare family-specific mutations to so-called
‘goldilocks’ alleles that segregate at low frequency in
the population.14 We evaluated a combination of both
models; this combination allowed frequencies between
:01% and 5% for risk variants. However, we showed that
our results also apply to analyses restricted to rarer variants
between 0:1% and 1%. Because we are interested in vari-
ants that would not be detected by existing association
methods, we assigned larger relative risks to rarer alleles.
Our results therefore apply to this class of risk variantser 12, 2010
Table 2. Summary of Empirical Distributions of Minor-Allele
Dosage for True Heterozygotes
Minor-Allele
Count in
Reference
Haplotypes
Fraction of Heterozygote Minor-Allele Dosages
<0.1 [0.1, 0.5) [0.5, 0.9) R 0.9
1 0.729 0.120 0.063 0.088
2 0.331 0.188 0.133 0.349
3 0.291 0.169 0.128 0.413
4 0.199 0.170 0.162 0.469
5 0.327 0.176 0.162 0.335
6 0.255 0.180 0.136 0.428
7 0.166 0.149 0.132 0.553and do not generalize to extremely rare variants with
Mendelian inheritance patterns. In particular, we note
that our choice of disease model explains the poor perfor-
mance of the private allele test, which is best suited for
testing highly penetrant Mendelian-like risk alleles segre-
gating within families. We have included it in our analysis
because it is currently one of the few statistical tests
that has successfully provided evidence for rare-variant
associations.
In summary, the CMAT is a powerful and versatile tool
for analyzing the contribution of rare variants to the heri-
tability of common complex diseases. The test accounts
for the uncertainty that imputation methods can confer
to genotypes and can be used for reanalyzing existing
GWAS datasets.
8 0.203 0.195 0.179 0.422
9 0.091 0.114 0.128 0.667
10 0.100 0.159 0.195 0.546
11–20 0.061 0.094 0.118 0.727
21–30 0.043 0.054 0.092 0.811
31–40 0.016 0.039 0.081 0.865
41–50 0.016 0.051 0.100 0.834
51–60 0.006 0.023 0.050 0.921
61–70 0.011 0.039 0.087 0.863
71–80 0.009 0.026 0.072 0.893
81–90 0.007 0.017 0.054 0.923
91–100 0.005 0.019 0.065 0.911
Each distribution is conditional on the indicated minor-allele count in the refer-
ence haplotypes. Here we report results for Nseq ¼ 100 sequenced cases and
controls.Appendix
Empirical Distributions for Expected Minor-Allele
Counts
We assume a set of cases and controls genotyped for a set of
tagSNPs across a 1 Mb segment that contains a 100 kb
region of interest. We assume that Nseq cases and controls
are randomly selected and sequenced at deep coverage in
the 100 kb region. Variants observed among the sequenced
samples in the region of interest are imputed into the
remaining samples.
We created empirical distributions of expected minor-
allele counts for imputed genotypes by assuming sequence
data for Nseq ¼ 100, 200, and 400 cases and controls and
tagSNPs for the remainder of the sample. For each, we first
simulated ten independent populations of ten thousand
1 Mb haplotypes by using cosi and for each region selected
a set of tagSNPsthat mimicked real-world tagging proper-
ties.22 For each 1 Mb region, the 100 selected tagSNPs
resulted in  78% of the common variants having an
r2R0:8 with one of the selected tagSNPs, similar to the
tagging properties of the Illumina HumanHap300 Bead-
Chip SNP genotyping platform. From each population,
we drew a random subset of 4000 haplotypes and treated
the first 2 3 Nseq as sequenced in the middle 100 kb region
of interest (these sample sizes correspond to datasets with
N ¼ 1000 and Nseq sequenced cases and controls).
We statistically phased the 23Nseq haplotypes across the
entire 1 Mb region. These phased haplotypes then served
as a reference panel for imputation of the variants observed
in the middle 100 kb into the remaining haplotypes.
Phasing and imputation were performed with the software
program MaCH.20 MaCH includes a ‘‘states’’ option that
speeds computation by limiting the number of haplotypes
considered at each iteration of phasing or imputation.
Because our analysis focused on rare variants that might
only appear on a few haplotypes, we did not use the states
shortcut. This probably prolonged computation time but
improved imputation accuracy.The AmericanWe observed that imputation accuracy for rare variants
was dependent on the allele frequency, the total number
of haplotypes in the reference panel (2 3 Nseq), and the
number of times a variant was observed in the reference
panel (M.Z. and S.Z., unpublished data). Therefore, we
created empirical sampling distributions by binning the
observed expected minor-allele counts (dosage) by true
underlying genotype and the number of times the minor
allele was observed in the reference panel. We pooled anal-
ogous distributions across all ten realizations to average
over varying degrees of LD. The distributions for true
heterozygotes were bimodal and had peaks at 1.0, the
true dosage for a heterozygote, and 0.0, the true dosage
for a major-allele homozygote. Because the minor allele
is observed more often in the reference panel, imputation
was more accurate, as indicated by fact that the density of
the peak at 0.0 shifted to larger dosage values. Table 2
summarizes these empirical distributions for Nseq ¼ 100.
The < 0:1 and R0:9 columns capture the density in the
two peaks. The distributions for true major-allele homozy-
gotes consist of a point mass at 0.0 and a small amount of
density just above 0.0. As the number of minor allelesJournal of Human Genetics 87, 604–617, November 12, 2010 615
observed in the reference panel increases, the density shifts
slightly away from the point mass.Supplemental Data
Supplemental Data include four figures and can be foundwith this
article online at http://www.cell.com/AJHG/.Acknowledgments
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